Research
Hormonal
GLP-1 RA initiation was associated with a reduced incidence of all-cause mortality post RYGB (1.2% vs. 3.9%) with a hazard ratio of 0.497.
Practitioners may consider GLP-1 RAs to potentially improve survival rates in patients post RYGB.
StrongSupportsmedium confidence
GLP-1 RA initiation was associated with a reduced incidence rate of all-cause mortality (1.2% versus 3.9%) (HR 0.497, [95% CI: 0.346-0.715, p = 0.039]).
Why this rating
Based on a multicenter retrospective cohort study design.
Source
Alcoholic Use Disorder Outcomes After <scp>Roux‐en‐Y</scp> Gastric Bypass in Patients Taking <scp>GLP</scp>‐<scp>1 RAs</scp>: A Multicenter Analysis
Olanrewaju Adeniran et al. · Obesity · 2025
DOI 10.1002/oby.70001
cohort · n=6876Cited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →